<DOC>
	<DOCNO>NCT00876902</DOCNO>
	<brief_summary>The study design assess feasibility evaluate YSPSL amelioration ischemia reperfusion injury follow liver transplantation administer YSPSL liver graft directly ex vivo via portal vein recipient intravenously prior reperfusion . This study extension recent pilot study YSPSL-0002 almost identical study protocol . The rationale previous study base recent observation P-selectin expression associate liver graft prolong cold storage time rejection . By examine biomarkers IRI include P-selectin immunohistochemistry and/or quantitative PCR , liver histology hepatic blood flow use establish technique , goal study evaluate feasibility use modality future study safety efficacy .</brief_summary>
	<brief_title>YSPSL Prevention Ischemic Reperfusion Injury Patients Undergoing Cadaveric Orthotopic Liver Transplantation</brief_title>
	<detailed_description>YSPSL-0003 extension 36 patient previous 12 patient pilot study YSPSL-0002 almost identical study protocol extend inclusion criterion . Like YSPSL-0002 , YSPSL-0003 single-center ( UCLA ) , randomize , placebo-controlled , double-blind study . Patients randomly assign either active study drug ( Active group ) placebo ( Control group ) prior transplantation . The active study drug dose include 1 mg/kg IV infusion recipient 20 mg [ approximately 0.27 mg/kg ] ex vivo flush . The dos administer via 2 separate infusion study agent : one 20 mg dose portal vein liver prior implantation ex vivo flush Viaspan® ; second infusion 1 mg/kg intravenously recipient , technically feasible , prior hepatic artery anastomosis . Placebo volume equivalent active study drug prepare administration control group help maintain blind . Those patient experience intraoperative blood loss &gt; 10 unit , receive additional 1 mg/kg IV infusion study agent ( placebo equivalent ) end transplant surgery . The Investigator/Sponsor blind treatment assignment patient . Randomization assignment maintain UCLA 's clinical pharmacist .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>Patient recipient primary ( first ) ABO compatible cadaveric liver allograft Patient 's age le 18 year Patient recipient multivisceral transplant simultaneous kidney transplant Patient undergone prior organ cellular transplant type Patient Model End Stage Liver Disease ( MELD ) score ≤38 Cold ischemia time ( CIT ) anticipate less 14 hour Donor liver procure UCLA liver team Venoveno bypass plan use patient ( e.g . prior surgery factor indicate risk excessive blood loss therefore need venoveno bypass +/ autologous recovery surgery ) For patient woman childbearing potential , patient negative pregnancy test ( either urine serum ) within 48 hour prior transplant Patient ( male female ) willing use acceptable form birth control least 3 month posttreatment Patient willing able sign inform consent . Patient prior organ transplant type Patient know allergic intolerance reaction human immune globulin , antibody , component formulation know contraindication administration YSPSL Patient uncontrolled active infection ( antibiotic control infection exclusion ) Patient active Hepatitis B virus ( HBV ) /transplant HBV related cirrhosis Patient previously participate study another study YSPSL Patient receive investigational therapy within 90 day prior transplant procedure Patient current drug alcohol abuse , opinion investigator , risk poor compliance visit protocol ( drug testing require ) Patient pregnant nursing female , female childbearing potential planning become pregnant within duration study , practice birth control Patient plan receive living donor liver transplant Patient live &gt; 200 mile away otherwise able participate study followup visit Donor body mass index &gt; 40 Donor liver biopsy &gt; 40 % macrosteatotic fat Donor age &gt; 70 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>liver transplantation</keyword>
	<keyword>cadaveric liver transplantation</keyword>
	<keyword>ischemic reperfusion injury</keyword>
	<keyword>primary non-function</keyword>
	<keyword>delay non-Function</keyword>
	<keyword>poor early graft function</keyword>
	<keyword>YSPSL</keyword>
	<keyword>recombinant PSGL-Ig</keyword>
</DOC>